TSEC:1789

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells CGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with proven track record.

Share Price & News

How has ScinoPharm Taiwan's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1789 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 1789's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

-5.6%

1789

-2.4%

TW Pharmaceuticals

2.5%

TW Market


1 Year Return

-10.0%

1789

28.2%

TW Pharmaceuticals

31.6%

TW Market

Return vs Industry: 1789 underperformed the TW Pharmaceuticals industry which returned 28.2% over the past year.

Return vs Market: 1789 underperformed the TW Market which returned 31.6% over the past year.


Shareholder returns

1789IndustryMarket
7 Day-5.6%-2.4%2.5%
30 Day-15.5%-10.2%11.8%
90 Day-19.5%-21.6%22.9%
1 Year-9.3%-10.0%30.4%28.2%36.3%31.6%
3 Year-28.0%-31.0%34.3%27.1%59.7%41.8%
5 Year-44.3%-47.4%6.4%-1.6%136.2%94.8%

Long-Term Price Volatility Vs. Market

How volatile is ScinoPharm Taiwan's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ScinoPharm Taiwan undervalued compared to its fair value and its price relative to the market?

9.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1789 (NT$24.3) is trading below our estimate of fair value (NT$26.86)

Significantly Below Fair Value: 1789 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 1789 is poor value based on its PE Ratio (59.5x) compared to the TW Pharmaceuticals industry average (17.3x).

PE vs Market: 1789 is poor value based on its PE Ratio (59.5x) compared to the TW market (18.4x).


Price to Earnings Growth Ratio

PEG Ratio: 1789 is poor value based on its PEG Ratio (2x)


Price to Book Ratio

PB vs Industry: 1789 is good value based on its PB Ratio (1.8x) compared to the TW Pharmaceuticals industry average (2x).


Next Steps

Future Growth

How is ScinoPharm Taiwan forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

30.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1789's forecast earnings growth (30.1% per year) is above the savings rate (0.8%).

Earnings vs Market: 1789's earnings (30.1% per year) are forecast to grow faster than the TW market (18.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1789's revenue (17.8% per year) is forecast to grow faster than the TW market (11.3% per year).

High Growth Revenue: 1789's revenue (17.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1789's Return on Equity is forecast to be low in 3 years time (6.7%).


Next Steps

Past Performance

How has ScinoPharm Taiwan performed over the past 5 years?

-20.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1789 has high quality earnings.

Growing Profit Margin: 1789's current net profit margins (10.7%) are higher than last year (8.9%).


Past Earnings Growth Analysis

Earnings Trend: 1789's earnings have declined by 20.6% per year over the past 5 years.

Accelerating Growth: 1789's earnings growth over the past year (23.6%) exceeds its 5-year average (-20.6% per year).

Earnings vs Industry: 1789 earnings growth over the past year (23.6%) exceeded the Pharmaceuticals industry 23.3%.


Return on Equity

High ROE: 1789's Return on Equity (3.1%) is considered low.


Next Steps

Financial Health

How is ScinoPharm Taiwan's financial position?


Financial Position Analysis

Short Term Liabilities: 1789's short term assets (NT$6.0B) exceed its short term liabilities (NT$881.6M).

Long Term Liabilities: 1789's short term assets (NT$6.0B) exceed its long term liabilities (NT$633.4M).


Debt to Equity History and Analysis

Debt Level: 1789's debt to equity ratio (2.3%) is considered satisfactory.

Reducing Debt: 1789's debt to equity ratio has reduced from 17.3% to 2.3% over the past 5 years.

Debt Coverage: 1789's debt is well covered by operating cash flow (315.5%).

Interest Coverage: 1789 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is ScinoPharm Taiwan current dividend yield, its reliability and sustainability?

1.11%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 1789's dividend (1.11%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (2.1%).

High Dividend: 1789's dividend (1.11%) is low compared to the top 25% of dividend payers in the TW market (5.16%).


Stability and Growth of Payments

Stable Dividend: 1789 is not paying a notable dividend for the TW market, therefore no need to check if payments are stable.

Growing Dividend: 1789 is not paying a notable dividend for the TW market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 1789 is not paying a notable dividend for the TW market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1789's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Tony Su (63 yo)

2.5yrs

Tenure

Mr. Tsung-Ming Su, also known as Tony, MBA has been President and Chief Executive Officer at ScinoPharm Taiwan, Ltd. July 05, 2018. Mr. Su serves as President of President International Development Corp., ...


Leadership Team

NamePositionTenureCompensationOwnership
Chih-Hsien Lo
Chairman & General Chief Strategy Officer3.42yrsno datano data
Tsung-Ming Su
President2.5yrsno datano data
Chih-Ching Hsu
Senior Director of Finance2.42yrsno datano data
Ling-Hsiao Lien
Vice-President of Operations1yrno datano data
Chih-Hui Lin
Senior Director of Accountingno datano datano data
Li-An Lu
Vice President of Administrationno datano datano data
Ching-Wen Lin
VP of Marketing & Sales and Chief Strategy Officer10.58yrsno data0.018%
NT$ 3.4m
Jessie Wang
Director of Human Resources & Administration11.33yrsno datano data
Li-Chiao Chang
VP of Injectable Business Division & Chief Scientific Officerno datano data0%
NT$ 0

3.0yrs

Average Tenure

Experienced Management: 1789's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Chih-Hsien Lo
Chairman & General Chief Strategy Officer3.42yrsno datano data
Tsung-Ming Su
President2.5yrsno datano data
Po-Ming Hou
Representative Director4.17yrsno datano data
Shiow-Ling Kao
Representative Director10.5yrsno datano data
Chiou-Ru Shih
Representative Director10.5yrsno datano data
Tsung-Pin Wu
Representative Director5.58yrsno datano data
Wei-te Ho
Independent Director8.58yrsno datano data
Kun-Shun Tsai
Representative Director5.58yrsno data0.00059%
NT$ 113.4k
Kuo-Hsi Wang
Director5yrsno datano data
Jia-Horng Guo
Representative Director3.42yrsno datano data
Li-Tzong Chen
Independent Director2.58yrsno datano data
Ming-Chuan Hsieh
Representative Director2.58yrsno datano data

5.3yrs

Average Tenure

Experienced Board: 1789's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ScinoPharm Taiwan, Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ScinoPharm Taiwan, Ltd.
  • Ticker: 1789
  • Exchange: TSEC
  • Founded: 1997
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$19.215b
  • Shares outstanding: 790.74m
  • Website: https://www.scinopharm.com

Location

  • ScinoPharm Taiwan, Ltd.
  • No. 1, Nan-Ke 8th Road
  • Southern Taiwan Science Park
  • Tainan City
  • 74144
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1789TSEC (Taiwan Stock Exchange)YesCommon StockTWTWDOct 2010

Biography

ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells CGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/23 08:38
End of Day Share Price2021/01/22 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.